Natural history and clinical outcome of differentiated thyroid carcinoma: A retrospective analysis of 1503 patients treated at a single institution

Annals of Oncology

Volumn 20, Issue 10, 2009, Pages 1728-1735

  Sciuto, R ^a   Romano, L ^a   Rea, S ^a   Marandino, F ^a   Sperduti, I ^a   Maini, C L ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Morbidity; Radioiodine therapy; Survival; Thyroid carcinoma

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAPILLARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SCHOOL CHILD; SURVIVAL RATE; SURVIVAL TIME; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; ITALY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349643417     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp050     Document Type: Article

References (30)

1. Mazzaferri EL, Kloos RT. Clinical Review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86: 1447-1463.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Database Report on 53,856 cases of thyroid carcinoma treated in U.S. 1985-1995. Cancer 1998; 83: 2638-2648.
3. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997; 79: 564-573.
4. Hay ID, Bergstralh EJ, Goellner JR et al. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 trough 1989. Surgery 1993; 114: 1050-1057.
5. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
6. Loh KC, Greenspan FS, Gee L et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas. J Clin Endocrinol Metab 1997; 82: 3553-3562.
7. De Groot LJ, Kaplan EL, Shukla MS et al. Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 1995; 80: 2946-2953.
8. Eustatia-Rutten CF, Corssmit EP, Biermasz NR et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 313-319.
9. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-2167.
10. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No.5 Lyon, France International Agency for Research on Cancer; 2001 http//www-dep.iarc.fr/ globocan/globocan.htm (3 November 2003, date last accessed).
11. Pacini F, Schlumberger M, Dralle H et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
12. Headinger C, Williams ED, Sobin LH (eds). Histological typing of thyroid tumors. In: International Histological Classification of Tumors, World Health Organization, 2nd edn Berlin: Springer-Verlag. 1988: 1-20.
13. Hermanek P, Sobin LH (eds). Thyroid gland (ICD-OC73). TNM classification of malignant tumors. In: International Union Against Cancer, 4th edn, 2nd revision., Berlin: Springer-Verlag. 1992: 35-37.
14. Rosai J. Poorly differentiated thyroid carcinoma: Introduction to the issue, its landmarks and clinical impact. Endocrine Pathol 2004; 15: 293-296.
15. Luster M, Clarke SE, Dietlein M et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. E J Nucl Mol Imaging 2008; 35: 1941-1959.
16. Maini CL, Sciuto R, Tofani A et al. Thyroid stimulating hormone (TSH) suppression in differentiated thyroid carcinoma: Combined treatment with triiodothyronine and thyroxine. Eur J Cancer 1994; 30A: 2184-2185.
17. Kuijpens JL, Hansen B, Hamming JF et al. Trends in treatment and in long term survival of thyroid cancer in southeastern Netherlands 1960-1992. Eur J Cancer 1998; 34: 1235-1241.
18. Eichhorn W, Tabler H, Lippold R et al. Prognostic factors determining long-term survival in well-differentiated thyroid cancer: An analysis of forty hundred eighty-four patients undergoing therapy and aftercare at the same Institution. Thyroid 2003; 13: 949-958.
19. Holzer S, Reiners C, Mann K et al. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group. Cancer 2000; 89: 192-201.
20. Surveillance, Epidemiology and End Results (SEER) Program. 2004 www.seer.cancer.gov. SEER stat database incidence- SEER 9 Regs Public-Use, Nov 2003 sub (1973-2001), National Cancer Institute, DCCPS, Surveillance research program, Cancer statistic branch, released 4/2004, based on 11/2003 submission National Cancer Institute.
21. Mirallie E, Visset J, Sagan C et al. Localization of cervical node metastases of papillary thyroid carcinoma. World J Surg 1999; 23: 970-973.
22. Schlumberger M, Tubiana M, De Vathaire F et al. Long term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63: 960-967.
23. Shah JP, Loree TR, Dharker D et al. Prognostic factors in differentiated thyroid carcinoma of the thyroid gland. Am J Surg 1992; 164: 658-661.
24. Hundahl SA, Cady B, Cunningham MP et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000; 89: 202-217.
25. Chow SM, Law SC, Au SK et al. Differentiated thyroid carcinoma: comparison between papillary and follicular in a single institute. Head Neck 2002; 24: 670-677.
26. Teppo L, Hakulinen T. Variation in survival of adult patients with thyroid cancer in Europe. EUROCARE Working Group. Eur J Cancer 1998; 34: 2248-2252.
27. Sant M, Aareleid T, Berrino F. EUROCARE Working Group. Eurocare-3: survival of cancer patients diagnosed 1990-1994-results and commentary. Ann Oncol 2003; 14 (Suppl 5): V61-v118.
28. Reynolds RM, Weir J, Stockton DL et al. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol 2005; 62: 156-62.
29. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995; 118: 1131-1136.
30. Hay ID, Mc Conahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: Insight gained from the Mayo Clinic's experience of treating 2512 consecutive patients during 1940 trough 2000. Trans Am Clin Climatol Assoc 2002; 113: 241-260.